Futura Medical worth double current value suggests research house
A major inflexion point will be the results of a pivotal Phase III study (FM57) for MED2005 in December.
Company
Futura Medical PLC
LON:FUM
Futura Medical specialises in the development and global commercialisation of innovative sexual health products, including lead product Eroxon®. The company's core strength lies in its research, development and commercialisation of topically delivered gel formulations in sexual health products.
305 stories · page 8 of 16
Futura Medical’s December trial data could be “game-changing”, says Liberum
The broker said the phase III clinical trial, which is expected to report by the middle of next month, had been “significantly de-risked” and had an over 70% chance of delivering a positive outcome
Futura Medical says latest data add to the growing body of evidence supporting its erectile dysfunction drug
MED2005, which is currently undergoing a phase III clinical trial, demonstrated a “dose-proportional” increases in penile blood flow
Archive
Proactive snapshot: Futura Medical, Echo Energy, Bluejay Mining
A look at some of the top stories from the Proactive newswire on Monday
Futura completes landmark ED phase III dosing, expects data by year end
In the same announcement, it said recruitment for a one-year, open-label extension study involving 1,000 men had been successfully concluded
Futura Medical to share data at US sexual medicine conference
The company will also host its third Scientific Advisory Meeting with high profile US key opinion leaders in the field of erectile dysfunction
Futura Medical on track with lead drug
The update in erectile dysfunction treatment MED2005 was provided alongside interim results
Futura Medical agrees joint venture to develop CBD product
“The benefits and applications of cannabis and cannabidiol in both the medical and consumer markets are well known and expanding rapidly," said Futura boss James Barder.
Archive
Proactive news snapshot: Kibo Energy, CentralNic, OptiBiotix Health...
A glance at some of the day's highlights from the Proactive Investors newswire
Futura Medical mulling fast-track European submission for lead drug candidate
Depending on the read-out from current study, it may opt to submit the results from just one phase III trial in Europe. But at this stage it is only considering this option
Investments and investor services
FTSE 100 closes shade higher as investors still fret about trade
On Wall Street, stocks were heading higher, through albeit with not much gusto
Archive
Small cap movers: Oil minnows sent gushing as drilling potentially unearths UK’s largest onshore gas field
A look back at some of this week's more interesting stories from London's junior market
Archive
News from FirstGroup, Stagecoach to drive corporate diary in coming week
Aside from the two mid-cap transport operators, blue chip contractor Bunzl will also issue a trading update, while the macro focus will be on the G20 meeting in Japan
Archive
Ted Baker tumbles to seven-year low as HSBC slashes target
A look at the day's major movers, including Ted Baker, IAG, easyJet, Bagir, Blue Prism, EVR, Blackbird, Nu-Oil & Gas, Anglo Asian Mining and Petrel Resources
Archive
Proactive news snapshot: Nu-Oil and Gas, Futura Medical, Anglo Asian Mining …
A glance at some of the day's highlights from the Proactive Investors newswire
Futura Medical completes recruitment for phase III erectile dysfunction treatment
A total of 1,000 men with mild, moderate and severe ED will be treated with MED2005
Archive
FTSE 100 slips at close as investors brace for US Fed decision
All eyes will be on the statement from Fed rate setters later, especially due to the pressure to lower rates from President Trump
Futura’s Phase 3 data for MED2005 could drive 500% share price upside, says Liberum
In an initiation note, Liberum’s analysts forecast peak sales potential for MED2002 at £500mln, ten times the company’s current market cap of £50mln
Futura Medical on the rise as Liberum says newspaper article could spark interest in group’s main ED product
Over the weekend The Guardian published an in-depth piece on the emerging treatments for erectile dysfunction (ED) with a significant focus on Futura's MED2005 product
Archive
Proactive news snapshot: Metal Tiger, BigDish, VR Education, Sound Energy …
A glance at some of the day's highlights from the Proactive Investors newswire